Compare FARM & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FARM | CING |
|---|---|---|
| Founded | 1912 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8M | 26.8M |
| IPO Year | N/A | 2021 |
| Metric | FARM | CING |
|---|---|---|
| Price | $1.48 | $3.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.75 | ★ $31.33 |
| AVG Volume (30 Days) | 67.7K | ★ 125.3K |
| Earning Date | 02-05-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $338,816,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $3.20 |
| 52 Week High | $3.29 | $6.01 |
| Indicator | FARM | CING |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 54.18 |
| Support Level | $1.44 | $3.81 |
| Resistance Level | $1.58 | $4.30 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 18.75 | 39.73 |
Farmer Bros Co is engaged in manufacturing, wholesaling, and distributing coffee, tea, and culinary products to food-service establishments and retailers in the United States. The company's customers include restaurants, hotels, offices, casinos, convenience stores, healthcare facilities, and other food-service providers. The company's product categories include roast and ground coffee, frozen liquid coffee, flavored and unflavored iced and hot teas, culinary products, spices, and other beverages, such as cappuccino, cocoa, granitas, and ready-to-drink iced coffee.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.